Enhanced anticancer effect of ABT-737 in combination with naringenin on gastric cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Gastric cancer is a leading cause of cancer mortality globally.
• Drug resistance in gastric cancer cells contributes to poor patient prognosis.
• Overexpression of B-cell lymphoma (Bcl)-2 is linked to drug resistance and poor outcomes.

Purpose of the Study:

• To investigate the combined anticancer effects of naringenin and the Bcl-2 inhibitor ABT-737.
• To evaluate the impact of this combination on gastric cancer cell growth and apoptosis.
• To explore the underlying molecular mechanisms involved in the observed effects.

Main Methods:

• Utilized the SGC7901 gastric cancer cell line.
• Assessed cell growth inhibition and colony formation assays.
• Measured the cleavage of caspase-3 and poly ADP-ribose polymerase (PARP).
• Analyzed Akt activation and p53 expression levels.

Main Results:

• Naringenin and ABT-737 demonstrated inhibitory effects on SGC7901 cell growth and colony formation, both individually and in combination.
• The combination treatment significantly increased the cleavage of caspase-3 and PARP, indicating enhanced apoptosis.
• Combined therapy led to decreased Akt activation and increased p53 expression.

Conclusions:

• Naringenin and ABT-737 exhibit synergistic anticancer activity against gastric cancer cells.
• The combination therapy promotes apoptosis through caspase-3 and PARP activation.
• Modulation of Akt and p53 pathways contributes to the observed anti-gastric cancer effects.